Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Total Non-Current Liabilities (2023 - 2025)

CG Oncology (CGON) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $37.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 73.9% year-over-year to $37.2 million, compared with a TTM value of $37.2 million through Dec 2025, up 73.9%, and an annual FY2025 reading of $37.2 million, up 73.9% over the prior year.
  • Total Non-Current Liabilities was $37.2 million for Q4 2025 at CG Oncology, down from $38.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $38.5 million in Q3 2025 and bottomed at $14.1 million in Q4 2023.
  • Average Total Non-Current Liabilities over 3 years is $27.8 million, with a median of $29.3 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 51.42% in 2024, then surged 73.9% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $14.1 million in 2023, then soared by 51.42% to $21.4 million in 2024, then soared by 73.9% to $37.2 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for CGON at $37.2 million in Q4 2025, $38.5 million in Q3 2025, and $21.4 million in Q4 2024.